Tweets
A#1748
Fracture incidence in RA - RISE registry
Incidence rate of MOF, hip Fx by disease activity
50% did not have CDAI available
IR 12 per 1000py hip, 43 for MOF
High activity worst, low/mod similar, remission is best
Supports remission is better than LDA
@RheumNow #ACR24 https://t.co/78FCLemfZD
Eric Dein @ericdeinmd ( View Tweet )
1 year 2 months ago
Ab1676 discussed an intervention to change patient mindsets about side-effects of #methotrexate. Watch my video for @RheumNow on this abstract here:
https://t.co/NxuxQ5wYda
#ACR24
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 2 months ago
Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato
Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH
Encouraging data for JAKs in this disease; need proper trials
#ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip
Links:
Mike Putman @EBRheum ( View Tweet )
1 year 2 months ago
Wu et al. MDA5-DM. Propensity-score cohort study. 672 patients. Tofacitinib vs CNI. Primary outcome 1 year death or lung transplant. HR 0.70 favouring tofacitinib. @RheumNow #ACR24 Abstr#1736 https://t.co/A0aHhp1q9c https://t.co/LbutJDBllr
Links:
Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
Can we do more to routinely assess fracture risk in RA?
In RA pts ≥65, hip fracture & MOF are more common in pts with active disease, worse with higher disease activity
➡️Need better and more frequent bone health assessments in our RA pts
Ab1748 #ACR24 @RheumNow https://t.co/whfnLnkpLd
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 2 months ago
A#1747
RA mortality by race/ethnicity
Database study
>200,000 pts had RA as contributing cause of death
5.1 ASMR in American Indian >>> all other groups
No decr over time in grp, unlike other grps
Odds of death 1.67 compared to white pop
10.8x higher in pts <44
#ACR24 @RheumNow https://t.co/nXLcQkQPu4
Links:
Eric Dein @ericdeinmd ( View Tweet )
1 year 2 months ago
On now: The Great Debate - is MCTD a distinct clinical entity?
@DrLisaCS reviews the history of MCTD classification criteria and its evolution
Kasukawa criteria may be most sensitive in one cohort
@RheumNow #ACR24 https://t.co/rDHafZVL1I
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
1 year 2 months ago
A study showed the sex differences in serum proteomic profiles of males and females with PsA.
Key findings:
-Identified 741 unique proteins in male PsA patients vs. controls vs. 31 in females.
- Several sex-specific pathways, including immune cell functions and cytokine… https://t.co/erC599Zbuj
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 2 months ago
Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec
Links:
Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
A#1746 companion for RA
Like plenary for PsA, PBO response incr w time 1%/yr
More trials in less affluent countries may be related to increasing PBO response in trials
Possible reason: access to health care improves PBO in less affluent areas
@RheumNow #ACR24 https://t.co/S3LffF8vPH
Eric Dein @ericdeinmd ( View Tweet )
1 year 2 months ago
RA patients on TOF with h/o ASCVD have 4x higher risk of MACE without statin (vs. TNFi).
Prioritize statins for heart health in RA!
#ACR24 @RheumNow ABST#1745 https://t.co/jRqXNU2T6d
Links:
Jiha Lee @JihaRheum ( View Tweet )
1 year 2 months ago
The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al.
axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed
@RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x
sheila @RHEUMarampa ( View Tweet )
1 year 2 months ago
